Phase 1 clinical trials are in reach that's if the company is being honest with its progress and not misleading shareholders.
Phase 1 is usually a small cohert of patients .
Investors would not be an issue if Phase 1 is successful .
Phase 2a and 2b is where it becomes alot more expensive and complicated .
They raised 9 million , some of which should be allocated to midkine developments .
If you read back over the years they should of been in clinical trials by now , but you already know that .
If Cellmid have misled shareholders regarding midkine developments then a class action is not out of question .